Rabia Gurses Ozden - Aug 2, 2024 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role: Chief Medical Officer
Signature: /s/ John Rakow, Attorney-in-Fact
Stock symbol: ADVM
Transactions as of: Aug 2, 2024
Transactions value $: $0
Form type: 4
Date filed: 8/6/2024, 04:10 PM
Previous filing: Jun 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADVM	Stock Option (Right to Buy)	Award	$0	+44K		$0.00	44K	Aug 2, 2024	Common Stock	44K	$7.15	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/3 of the total number of shares subject to the Option shall vest and become exercisable on the first anniversary of August 2, 2024 (the "Vesting Commencement Date"), and 1/36 of the total number of shares subject to the Option shall vest and become exercisable each month thereafter, such that all of the shares shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

Content

1/3 of the total number of shares subject to the Option shall vest and become exercisable on the first anniversary of August 2, 2024 (the "Vesting Commencement Date"), and 1/36 of the total number of shares subject to the Option shall vest and become exercisable each month thereafter, such that all of the shares shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.